首页 > 最新文献

Journal of Infection and Chemotherapy最新文献

英文 中文
Effect of studying abroad on catch-up vaccination in young adults: A study using the Japan Pretravel Consultation Registry. 出国留学对年轻人补种疫苗的影响:利用日本旅行前咨询登记处进行的研究1。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-10-30 DOI: 10.1016/j.jiac.2024.10.015
Nobumasa Okumura, Kei Yamamoto, Noriko Iwamoto, Shinya Tsuzuki, Kenichi Hayashi, Koh Shinohara, Issaku Nakatani, Hidenori Nakagawa, Natsuko Imakita, Takashi Matono, Akihiro Manabe, Tsuyoshi Kitaura, Takahiro Mikawa, Masaya Yamato, Norio Ohmagari

Purpose: To investigate the effect of studying abroad on catch-up vaccination coverage for measles, rubella, mumps, varicella, and tetanus during the pretravel consultation among young adult travelers.

Methods: This retrospective cohort study analyzed data from the Japan Pretravel Consultation Registry (J-PRECOR) on individuals aged 18-21 years with childhood vaccination records. Propensity score weighting was used to estimate the average treatment effect on the proportion of participants receiving catch-up vaccination.

Results: Among 1091 eligible participants, the catch-up vaccination need was highest for mumps (65.7 %) and varicella (49.0 %) and lowest for measles (9.9 %) and rubella (14.0 %). In the unadjusted analysis, the catch-up vaccination rate was 70.6 % for tetanus, 50.9 % for measles, 47.7 % for rubella, 40.0 % for mumps, and 23.9 % for varicella. In the weighted analysis, the study-abroad group had significantly higher catch-up vaccination rates for measles (54.6 % vs. 29.8 %, P = 0.039), rubella (53.0 % vs. 22.1 %, P < 0.001), and varicella (26.8 % vs. 10.9 %, P = 0.002), whereas the non-study-abroad group had a higher catch-up vaccination rate for tetanus (62.4 % vs. 78.4 %, P = 0.024).

Conclusion: Compared with other travelers, the catch-up vaccination rate among travelers studying abroad was higher for measles, rubella, and varicella, but lower for tetanus. In clients planning to study abroad, vaccinations required for travel should be recommended in addition to those required by the host institution, and vaccination against highly infectious diseases with potential for complications, such as measles, rubella, mumps, and varicella, should be recommended to clients traveling for reasons other than studying abroad.

目的:研究出国留学对年轻成人旅行者旅行前咨询期间麻疹、风疹、腮腺炎、水痘和破伤风疫苗补种覆盖率的影响:这项回顾性队列研究分析了日本旅行前咨询登记处(J-PRECOR)的数据,研究对象是有儿童疫苗接种记录的 18-21 岁的个人。研究采用倾向得分加权法估算了对接受补种的参与者比例的平均治疗效果:在 1091 名符合条件的参与者中,流行性腮腺炎(65.7%)和水痘(49.0%)的补种需求最高,麻疹(9.9%)和风疹(14.0%)的补种需求最低。在未调整分析中,破伤风的补种率为 70.6%,麻疹为 50.9%,风疹为 47.7%,流行性腮腺炎为 40.0%,水痘为 23.9%。在加权分析中,出国留学组的麻疹(54.6% 对 29.8%,P = 0.039)、风疹(53.0% 对 22.1%,P < 0.001)和水痘(26.8% 对 10.9%,P = 0.002)补种率明显较高,而非出国留学组的破伤风补种率较高(62.4% 对 78.4%,P = 0.024):结论:与其他旅行者相比,出国留学人员的麻疹、风疹和水痘疫苗补种率较高,但破伤风疫苗补种率较低。对于计划出国留学的人,除了建议他们接种所在机构要求的疫苗外,还应建议他们接种旅行所需的疫苗,并建议因留学以外的原因出国的人接种麻疹、风疹、流行性腮腺炎和水痘等可能引起并发症的高传染性疾病的疫苗。
{"title":"Effect of studying abroad on catch-up vaccination in young adults: A study using the Japan Pretravel Consultation Registry.","authors":"Nobumasa Okumura, Kei Yamamoto, Noriko Iwamoto, Shinya Tsuzuki, Kenichi Hayashi, Koh Shinohara, Issaku Nakatani, Hidenori Nakagawa, Natsuko Imakita, Takashi Matono, Akihiro Manabe, Tsuyoshi Kitaura, Takahiro Mikawa, Masaya Yamato, Norio Ohmagari","doi":"10.1016/j.jiac.2024.10.015","DOIUrl":"10.1016/j.jiac.2024.10.015","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the effect of studying abroad on catch-up vaccination coverage for measles, rubella, mumps, varicella, and tetanus during the pretravel consultation among young adult travelers.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed data from the Japan Pretravel Consultation Registry (J-PRECOR) on individuals aged 18-21 years with childhood vaccination records. Propensity score weighting was used to estimate the average treatment effect on the proportion of participants receiving catch-up vaccination.</p><p><strong>Results: </strong>Among 1091 eligible participants, the catch-up vaccination need was highest for mumps (65.7 %) and varicella (49.0 %) and lowest for measles (9.9 %) and rubella (14.0 %). In the unadjusted analysis, the catch-up vaccination rate was 70.6 % for tetanus, 50.9 % for measles, 47.7 % for rubella, 40.0 % for mumps, and 23.9 % for varicella. In the weighted analysis, the study-abroad group had significantly higher catch-up vaccination rates for measles (54.6 % vs. 29.8 %, P = 0.039), rubella (53.0 % vs. 22.1 %, P < 0.001), and varicella (26.8 % vs. 10.9 %, P = 0.002), whereas the non-study-abroad group had a higher catch-up vaccination rate for tetanus (62.4 % vs. 78.4 %, P = 0.024).</p><p><strong>Conclusion: </strong>Compared with other travelers, the catch-up vaccination rate among travelers studying abroad was higher for measles, rubella, and varicella, but lower for tetanus. In clients planning to study abroad, vaccinations required for travel should be recommended in addition to those required by the host institution, and vaccination against highly infectious diseases with potential for complications, such as measles, rubella, mumps, and varicella, should be recommended to clients traveling for reasons other than studying abroad.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102547"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic drug monitoring of azole antifungal agents. 唑类抗真菌药物的治疗药物监测。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-10-05 DOI: 10.1016/j.jiac.2024.10.003
Yukihiro Hamada, Yusuke Yagi

Deep-seated mycoses are generally opportunistic infections that are difficult to diagnose and treat. They are expected to increase with the spread of advanced medical care and aging populations, thus highlighting the need for safe, effective, and rapid drug-based treatments. Depending on a patient's age, sex, underlying diseases, and immune system status, therapeutic drug monitoring (TDM) may be important for assessing variable pharmacokinetic parameters, as well as preventing drug-drug interactions, adverse events, and breakthrough infections caused by fungal resistance. Azole antifungal agents play an important role in the prevention and treatment of deep-seated fungal infections, with each azoles having its own unique pharmacokinetic properties and specific adverse events. Therefore, it is necessary to use national and international guidelines to build evidence for the expansion of TDM indications. This review focuses on the clinical utility and future perspectives of TDM using azole antifungal agents, in the context of recent evidence in the literature.

深部真菌病通常是难以诊断和治疗的机会性感染。随着先进医疗技术的普及和人口老龄化的加剧,预计这类真菌病会越来越多,因此需要安全、有效和快速的药物治疗。根据患者的年龄、性别、基础疾病和免疫系统状况,治疗药物监测(TDM)对于评估可变的药代动力学参数以及预防药物间相互作用、不良事件和真菌耐药性引起的突破性感染可能非常重要。唑类抗真菌药物在预防和治疗深部真菌感染中发挥着重要作用,每种唑类药物都有其独特的药代动力学特性和特定的不良反应。因此,有必要利用国家和国际指南为扩大 TDM 适应症提供证据。本综述结合最新文献证据,重点探讨了使用唑类抗真菌药物进行 TDM 的临床实用性和未来前景。
{"title":"Therapeutic drug monitoring of azole antifungal agents.","authors":"Yukihiro Hamada, Yusuke Yagi","doi":"10.1016/j.jiac.2024.10.003","DOIUrl":"10.1016/j.jiac.2024.10.003","url":null,"abstract":"<p><p>Deep-seated mycoses are generally opportunistic infections that are difficult to diagnose and treat. They are expected to increase with the spread of advanced medical care and aging populations, thus highlighting the need for safe, effective, and rapid drug-based treatments. Depending on a patient's age, sex, underlying diseases, and immune system status, therapeutic drug monitoring (TDM) may be important for assessing variable pharmacokinetic parameters, as well as preventing drug-drug interactions, adverse events, and breakthrough infections caused by fungal resistance. Azole antifungal agents play an important role in the prevention and treatment of deep-seated fungal infections, with each azoles having its own unique pharmacokinetic properties and specific adverse events. Therefore, it is necessary to use national and international guidelines to build evidence for the expansion of TDM indications. This review focuses on the clinical utility and future perspectives of TDM using azole antifungal agents, in the context of recent evidence in the literature.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102535"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of direct identification of bacteria in blood culture-positive specimens by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry on physician selection of antimicrobial therapy. 基质辅助激光解吸附/电离飞行时间质谱法直接鉴定血培养阳性标本中的细菌对医生选择抗菌疗法的影响。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-10-30 DOI: 10.1016/j.jiac.2024.10.016
Hiroshi Umemura, Hiroyuki Nishiyama, Yumiko Tanimichi, Kohgo Seino, Masaki Nakajima, Sachio Tsuchida, Tomohiro Nakayama

Background: Rapid identification of the causative organism in blood stream infections is essential for early initiation of appropriate antimicrobial therapy. Direct identification of bacteria in positive blood culture bottles using matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry is a promising application. A variety of direct identification methods have been reported; however, few studies have evaluated the impact of these methods on physician decision making regarding antimicrobial therapy.

Methods: We developed a simple method for direct bacterial identification and applied it to daily clinical practice to investigate the impact of direct identification of bacteria in positive blood culture bottles on physicians' choice of antimicrobial agents for treatment.

Results: From January 2016 to December 2022, we attempted direct identification in 98 cases and successfully acquired identification results in 88 cases. In three cases, no empiric antimicrobial agents were initiated at the time of venipuncture for blood culture but later initiated based on the direct identification results. In the remaining 85 cases, empiric antimicrobial therapy was initiated at the time blood cultures were performed, and in 29 cases, empiric antimicrobial therapy was changed after direct identification. In 17 of these 29 cases, the antimicrobial therapy was changed based on the direct identification of bacterial genus/species, resulting in a change to an effective antimicrobial therapy before the antimicrobial susceptibility testing results were available.

Conclusions: Direct identification of bacteria from positive blood culture bottles could contribute to earlier selection of or changes to antimicrobial therapies by attending physicians.

背景:快速鉴定血流感染中的致病菌对于及早启动适当的抗菌治疗至关重要。使用基质辅助激光解吸/电离飞行时间质谱法直接鉴定阳性血培养瓶中的细菌是一种很有前景的应用。目前已报道了多种直接鉴定方法,但很少有研究评估这些方法对医生抗菌治疗决策的影响:方法:我们开发了一种简单的细菌直接鉴定方法,并将其应用于日常临床实践,研究直接鉴定血培养阳性瓶中细菌对医生选择抗菌药物治疗的影响:从2016年1月至2022年12月,我们尝试对98个病例进行直接鉴定,并成功获得88个病例的鉴定结果。在 3 个病例中,静脉穿刺进行血培养时未使用经验性抗菌药物,但后来根据直接鉴定结果使用了抗菌药物。在其余 85 例病例中,经验性抗菌药物治疗是在进行血液培养时启动的,29 例病例的经验性抗菌药物治疗是在直接鉴定后更改的。在这 29 个病例中,有 17 个病例的抗菌治疗是根据细菌属/种的直接鉴定结果而改变的,结果在抗菌药物敏感性检测结果出来之前,就已经改用了有效的抗菌治疗:结论:从阳性血培养瓶中直接鉴定细菌有助于主治医生更早地选择或改变抗菌疗法。
{"title":"Impact of direct identification of bacteria in blood culture-positive specimens by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry on physician selection of antimicrobial therapy.","authors":"Hiroshi Umemura, Hiroyuki Nishiyama, Yumiko Tanimichi, Kohgo Seino, Masaki Nakajima, Sachio Tsuchida, Tomohiro Nakayama","doi":"10.1016/j.jiac.2024.10.016","DOIUrl":"10.1016/j.jiac.2024.10.016","url":null,"abstract":"<p><strong>Background: </strong>Rapid identification of the causative organism in blood stream infections is essential for early initiation of appropriate antimicrobial therapy. Direct identification of bacteria in positive blood culture bottles using matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry is a promising application. A variety of direct identification methods have been reported; however, few studies have evaluated the impact of these methods on physician decision making regarding antimicrobial therapy.</p><p><strong>Methods: </strong>We developed a simple method for direct bacterial identification and applied it to daily clinical practice to investigate the impact of direct identification of bacteria in positive blood culture bottles on physicians' choice of antimicrobial agents for treatment.</p><p><strong>Results: </strong>From January 2016 to December 2022, we attempted direct identification in 98 cases and successfully acquired identification results in 88 cases. In three cases, no empiric antimicrobial agents were initiated at the time of venipuncture for blood culture but later initiated based on the direct identification results. In the remaining 85 cases, empiric antimicrobial therapy was initiated at the time blood cultures were performed, and in 29 cases, empiric antimicrobial therapy was changed after direct identification. In 17 of these 29 cases, the antimicrobial therapy was changed based on the direct identification of bacterial genus/species, resulting in a change to an effective antimicrobial therapy before the antimicrobial susceptibility testing results were available.</p><p><strong>Conclusions: </strong>Direct identification of bacteria from positive blood culture bottles could contribute to earlier selection of or changes to antimicrobial therapies by attending physicians.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102548"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antimicrobial Combinations as Novel Indicators for Clostridioides difficile infection development: Population-Based, Nested Case-Controlled Study in Japan-The Shizuoka Kokuho Database Study. 作为艰难梭菌感染发展新指标的抗菌药组合:日本基于人群的嵌套病例对照研究--静冈国宝数据库研究》。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-11-06 DOI: 10.1016/j.jiac.2024.11.002
Takashi Saito, Yoko Sato, Seiichiro Yamamoto

Background: Clostridioides difficile is a major cause of antimicrobial-associated colitis. While antimicrobial stewardship has reduced the incidence of C. difficile infection (CDI), managing CDI is challenging because knowledge about preventing it is limited among healthcare professionals. To address this, we examined associations between antimicrobial use and CDI development.

Methods: This observational, nested case-controlled study was conducted using the Shizuoka Kokuho Database (SKDB). Individuals with no record of CDI or antimicrobial-associated enterocolitis within 1 year after SKDB enrolment, but who subsequently developed CDI, were included as the Case group. The Control group comprised individuals selected via 1:4 matching sampling without replacement for sex, age, and month of CDI onset. Conditional logistic regression analysis was performed to assess associations between antimicrobial use (number and combination) and CDI development, controlling for matched variables, background factors, and underlying conditions.

Results: Of the 2,398,393 individuals, 4917 were assigned to the Case group and 19,668 to the Control group. The adjusted odds ratios (ORs) for CDI were 3.65 for one antimicrobial and 8.58, 17.3, and 38.9 for combinations of two, three, or four or more agents (all p < 0.001). Penicillins, fourth-generation cephems, and carbapenems exhibited high ORs. Similar results were observed in certain demographic and comorbidity-free subgroups. Several combinations (penicillins + carbapenems, penicillins + cephems + carbapenems, cephems + fluoroquinolones, and penicillins + cephems + carbapenems) were notably associated with CDI development.

Conclusion: CDI prevalence increased with the number of antimicrobial classes used in combination. Certain types or combinations of antimicrobials may increase the OR for CDI.

背景:艰难梭菌是导致抗菌药物相关性结肠炎的主要原因。虽然抗菌药物管理降低了艰难梭菌感染(CDI)的发病率,但由于医护人员对预防艰难梭菌感染的知识有限,因此管理艰难梭菌感染仍具有挑战性。为了解决这个问题,我们研究了抗菌药物使用与 CDI 发病之间的关系:这项观察性、巢式病例对照研究是利用静冈国宝数据库(SKDB)进行的。病例组包括在加入 SKDB 后 1 年内没有 CDI 或抗菌药物相关性小肠结肠炎记录,但随后患上 CDI 的患者。对照组包括通过 1:4 匹配抽样选出的个体,不对性别、年龄和 CDI 发病月份进行替换。在控制匹配变量、背景因素和基础疾病的情况下,进行了条件逻辑回归分析,以评估抗菌药物使用(数量和组合)与 CDI 发病之间的关联:在 2,398,393 人中,4917 人被分配到病例组,19668 人被分配到对照组。使用一种抗菌药的 CDI 调整后几率比(ORs)为 3.65,使用两种、三种或四种以上抗菌药的调整后几率比(ORs)分别为 8.58、17.3 和 38.9(均为 p):CDI 感染率随着联合使用的抗菌药物种类的增加而增加。某些类型或组合的抗菌药物可能会增加 CDI 的发生率。
{"title":"Antimicrobial Combinations as Novel Indicators for Clostridioides difficile infection development: Population-Based, Nested Case-Controlled Study in Japan-The Shizuoka Kokuho Database Study.","authors":"Takashi Saito, Yoko Sato, Seiichiro Yamamoto","doi":"10.1016/j.jiac.2024.11.002","DOIUrl":"10.1016/j.jiac.2024.11.002","url":null,"abstract":"<p><strong>Background: </strong>Clostridioides difficile is a major cause of antimicrobial-associated colitis. While antimicrobial stewardship has reduced the incidence of C. difficile infection (CDI), managing CDI is challenging because knowledge about preventing it is limited among healthcare professionals. To address this, we examined associations between antimicrobial use and CDI development.</p><p><strong>Methods: </strong>This observational, nested case-controlled study was conducted using the Shizuoka Kokuho Database (SKDB). Individuals with no record of CDI or antimicrobial-associated enterocolitis within 1 year after SKDB enrolment, but who subsequently developed CDI, were included as the Case group. The Control group comprised individuals selected via 1:4 matching sampling without replacement for sex, age, and month of CDI onset. Conditional logistic regression analysis was performed to assess associations between antimicrobial use (number and combination) and CDI development, controlling for matched variables, background factors, and underlying conditions.</p><p><strong>Results: </strong>Of the 2,398,393 individuals, 4917 were assigned to the Case group and 19,668 to the Control group. The adjusted odds ratios (ORs) for CDI were 3.65 for one antimicrobial and 8.58, 17.3, and 38.9 for combinations of two, three, or four or more agents (all p < 0.001). Penicillins, fourth-generation cephems, and carbapenems exhibited high ORs. Similar results were observed in certain demographic and comorbidity-free subgroups. Several combinations (penicillins + carbapenems, penicillins + cephems + carbapenems, cephems + fluoroquinolones, and penicillins + cephems + carbapenems) were notably associated with CDI development.</p><p><strong>Conclusion: </strong>CDI prevalence increased with the number of antimicrobial classes used in combination. Certain types or combinations of antimicrobials may increase the OR for CDI.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102552"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human Papillomavirus vaccination awareness and uptake among healthcare students in Japan. 日本医学生对人类乳头瘤病毒疫苗接种的认识和接受情况。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-11-05 DOI: 10.1016/j.jiac.2024.11.004
Madoka Shimbe, Yuki Otsuka, Hideharu Hagiya, Yoichi Yamada, Fumio Otsuka

Background: The vaccination rate for HPV (Human Papillomavirus) has remained significantly low in Japan because of the administrative suspension of active recommendation. This study investigates the awareness and uptake of the HPV vaccine among healthcare students in Japan following the reinstatement of active recommendation for young women in April 2022.

Methods: A web-based survey was administered to 2567 healthcare students from Okayama and Shujitsu Universities in Japan in July 2023. The survey assessed participants' backgrounds, immunization status, awareness of vaccine recommendations, and knowledge of cervical cancer across various demographics, including sex, academic year, and department (Medicine, Health Science, Pharmaceutical, and Dentistry).

Results: The response rate was 36.3 % (933 students; 181 male, 739 female, and 13 unspecified gender). The overall immunization rate among female students was 55.6 %, with higher rates observed in medical (73.8 %) and dental (63.0 %) students. Awareness of the government's change in vaccine recommendation was notably high among female and senior male students. Over half of the female students (54.7 %) reported receiving vaccinations based on their parents' advice. Among those unvaccinated but interested in future immunization, concerns about adverse reactions (47.4 %) and challenges in scheduling vaccinations (29.1 %) were predominant.

Conclusion: Healthcare students exhibited a higher HPV vaccination rate than the general population. Ongoing education to improve vaccine literacy is crucial for augmenting HPV vaccination rates in Japan.

背景:由于主动推荐的行政暂停,日本的人乳头瘤病毒(HPV)疫苗接种率一直很低。本研究调查了 2022 年 4 月恢复对年轻女性的积极推荐后,日本医学生对 HPV 疫苗的认识和接种情况:方法:2023 年 7 月,对日本冈山大学和修缮大学的 2567 名医学生进行了网络调查。调查评估了参与者的背景、免疫接种状况、对疫苗建议的认识以及对宫颈癌的了解,包括性别、学年和院系(医学、健康科学、药学和牙科学)等不同人口统计学特征:答复率为 36.3%(933 名学生;181 名男生、739 名女生和 13 名未指明性别的学生)。女生的总体免疫接种率为 55.6%,其中医科学生(73.8%)和牙科学生(63.0%)的免疫接种率较高。女生和高年级男生对政府改变疫苗接种建议的知晓率明显较高。超过一半的女生(54.7%)表示根据父母的建议接种了疫苗。在未接种疫苗但对未来免疫接种感兴趣的学生中,对不良反应的担忧(47.4%)和接种时间安排上的困难(29.1%)占主导地位:结论:医学生的 HPV 疫苗接种率高于普通人群。持续开展教育以提高疫苗接种知识对提高日本的 HPV 疫苗接种率至关重要。
{"title":"Human Papillomavirus vaccination awareness and uptake among healthcare students in Japan.","authors":"Madoka Shimbe, Yuki Otsuka, Hideharu Hagiya, Yoichi Yamada, Fumio Otsuka","doi":"10.1016/j.jiac.2024.11.004","DOIUrl":"10.1016/j.jiac.2024.11.004","url":null,"abstract":"<p><strong>Background: </strong>The vaccination rate for HPV (Human Papillomavirus) has remained significantly low in Japan because of the administrative suspension of active recommendation. This study investigates the awareness and uptake of the HPV vaccine among healthcare students in Japan following the reinstatement of active recommendation for young women in April 2022.</p><p><strong>Methods: </strong>A web-based survey was administered to 2567 healthcare students from Okayama and Shujitsu Universities in Japan in July 2023. The survey assessed participants' backgrounds, immunization status, awareness of vaccine recommendations, and knowledge of cervical cancer across various demographics, including sex, academic year, and department (Medicine, Health Science, Pharmaceutical, and Dentistry).</p><p><strong>Results: </strong>The response rate was 36.3 % (933 students; 181 male, 739 female, and 13 unspecified gender). The overall immunization rate among female students was 55.6 %, with higher rates observed in medical (73.8 %) and dental (63.0 %) students. Awareness of the government's change in vaccine recommendation was notably high among female and senior male students. Over half of the female students (54.7 %) reported receiving vaccinations based on their parents' advice. Among those unvaccinated but interested in future immunization, concerns about adverse reactions (47.4 %) and challenges in scheduling vaccinations (29.1 %) were predominant.</p><p><strong>Conclusion: </strong>Healthcare students exhibited a higher HPV vaccination rate than the general population. Ongoing education to improve vaccine literacy is crucial for augmenting HPV vaccination rates in Japan.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102554"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aspergillus spondylodiscitis successfully treated with a long course of isavuconazole. 长疗程的异戊康唑治疗曲霉菌性脊柱炎成功。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-11-28 DOI: 10.1016/j.jiac.2024.11.017
Francisco Javier Teigell Muñoz, Ana Sánchez-de Torre, Marta Jiménez-Fernández, Lorenzo Zuñiga Gómez, María Mateos-González, Abdulhamit Batiray Polat, Jesús Fortún Abete

We present a case of spondylodiscitis caused by Aspergillus fumigatus, which we successfully treated with isavuconazole after voriconazole severe intolerance. Aspergillus spondylodiscitis is a severe and relatively rare form of extra-pulmonary invasive aspergillosis. Typically, voriconazole is the first-choice antifungal drug for treating Aspergillus osteomyelitis or spondylodiscitis. However, isavuconazole, a new antifungal medication, has been demonstrated as non-inferior to voriconazole in cases of invasive aspergillosis. It has the added benefits of fewer hepatobiliary, ocular, and cutaneous side effects. It generally does not demand serum level monitoring and poses fewer risks of drug interactions. Nonetheless, there are no studies yet that support its use in spondylodiscitis, and published experiences are very limited and based on isolated cases, albeit mainly positive. The case we present here aims to provide additional evidence on the efficacy and tolerability of isavuconazole in treating this condition.

我们报告了一例由烟曲霉引起的脊柱炎,我们在伏立康唑严重不耐受后成功地用异戊康唑治疗。曲霉菌性脊柱炎是一种严重且相对罕见的肺外侵袭性曲霉菌病。通常,伏立康唑是治疗曲霉菌性骨髓炎或脊椎椎间盘炎的首选抗真菌药物。然而,isavuconazole,一种新的抗真菌药物,已被证明在侵袭性曲霉病的病例中不逊于voriconazole。它还具有更少的肝胆、眼部和皮肤副作用。它通常不需要监测血清水平,并且药物相互作用的风险较小。尽管如此,目前还没有研究支持其在脊柱炎中的应用,已发表的经验非常有限,而且是基于孤立的病例,尽管主要是积极的。我们在这里提出的病例旨在为异戊康唑治疗这种疾病的疗效和耐受性提供额外的证据。
{"title":"Aspergillus spondylodiscitis successfully treated with a long course of isavuconazole.","authors":"Francisco Javier Teigell Muñoz, Ana Sánchez-de Torre, Marta Jiménez-Fernández, Lorenzo Zuñiga Gómez, María Mateos-González, Abdulhamit Batiray Polat, Jesús Fortún Abete","doi":"10.1016/j.jiac.2024.11.017","DOIUrl":"10.1016/j.jiac.2024.11.017","url":null,"abstract":"<p><p>We present a case of spondylodiscitis caused by Aspergillus fumigatus, which we successfully treated with isavuconazole after voriconazole severe intolerance. Aspergillus spondylodiscitis is a severe and relatively rare form of extra-pulmonary invasive aspergillosis. Typically, voriconazole is the first-choice antifungal drug for treating Aspergillus osteomyelitis or spondylodiscitis. However, isavuconazole, a new antifungal medication, has been demonstrated as non-inferior to voriconazole in cases of invasive aspergillosis. It has the added benefits of fewer hepatobiliary, ocular, and cutaneous side effects. It generally does not demand serum level monitoring and poses fewer risks of drug interactions. Nonetheless, there are no studies yet that support its use in spondylodiscitis, and published experiences are very limited and based on isolated cases, albeit mainly positive. The case we present here aims to provide additional evidence on the efficacy and tolerability of isavuconazole in treating this condition.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102567"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Escherichia coli with increased aminoglycoside resistance due to an amino acid substitution at position 85 of HemC. 由于 HemC 第 85 位的氨基酸替换,大肠杆菌对氨基糖苷类药物的耐药性增强。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-10-05 DOI: 10.1016/j.jiac.2024.10.004
Tomoki Komeda, Tomomi Hishinuma, Teruo Kirikae, Tatsuya Tada

Objective: The mechanism of aminoglycoside resistance due to abnormal hemin synthesis remains unclear. We investigate an Escherichia coli strain with a single amino acid substitution at position 85 of HemC.

Methods: An aminoglycoside-resistant Escherichia coli DH5α was selected by passaging in Lysogeny Broth (LB) medium containing amikacin. Whole genome sequencing was performed to determine the genetic profile of the strain. An isogenic strain of E. coli DH5α was created. Growth rates, drug susceptibilities and expressions of the heme synthetic genes were compared between the original strain and the isogenic strain.

Results: Whole genome sequencing revealed a nucleotide substitution at position 254 of hemC from adenine (A) to thymine (T), resulting in an amino acid substitution at position 85 of HemC from histidine (H) to leucine (L). There were no mutations in other heme synthetic genes, including hemA, hemB, hemC, hemD, hemE, hemF, hemG, hemH, hemL, hemN, hemX and hemY. The isogenic strain of E. coli DH5α with H85L in HemC was less susceptible to aminoglycosides, and its growth was slower than that of E. coli DH5α before passage. Quantitative real-time PCR showed that the expression of hemA was higher and the expressions of hemL, hemG and hemX lower in the isogenic strain than before passage.

Conclusion: This is the first report of aminoglycoside resistance due to an amino acid substitution in HemC. These findings suggested that mutations in the heme synthetic genes may indirectly affect the growth rates of E. coli strains and their susceptibilities to aminoglycosides.

目的:氨基糖苷类药物因血氨合成异常而产生耐药性的机制尚不清楚。我们研究了一株在 HemC 的第 85 位进行了单个氨基酸置换的大肠杆菌:方法:通过在含阿米卡星的溶菌酶肉汤(LB)培养基中传代,筛选出对氨基糖苷类耐药的大肠埃希菌 DH5α。进行了全基因组测序,以确定菌株的遗传特征。建立了大肠杆菌 DH5α 的同源菌株。比较了原始菌株和异源菌株的生长率、药物敏感性和血红素合成基因的表达:结果:全基因组测序发现 HemC 第 254 位的核苷酸从腺嘌呤(A)替换为胸腺嘧啶(T),导致 HemC 第 85 位的氨基酸从组氨酸(H)替换为亮氨酸(L)。其他血红素合成基因(包括 hemA、hemB、hemC、hemD、hemE、hemF、hemG、hemH、hemL、hemN、hemX 和 hemY)没有发生突变。HemC中含有H85L的大肠杆菌DH5α同源菌株对氨基糖苷类药物的敏感性较低,其生长速度比通过前的大肠杆菌DH5α慢。实时定量 PCR 显示,与通过前相比,同源菌株中 hemA 的表达量较高,而 hemL、hemG 和 hemX 的表达量较低:结论:这是首次报道由于 HemC 中的氨基酸替换而导致的氨基糖苷类耐药性。这些发现表明,血红素合成基因的突变可能会间接影响大肠杆菌菌株的生长速度及其对氨基糖苷类药物的敏感性。
{"title":"Escherichia coli with increased aminoglycoside resistance due to an amino acid substitution at position 85 of HemC.","authors":"Tomoki Komeda, Tomomi Hishinuma, Teruo Kirikae, Tatsuya Tada","doi":"10.1016/j.jiac.2024.10.004","DOIUrl":"10.1016/j.jiac.2024.10.004","url":null,"abstract":"<p><strong>Objective: </strong>The mechanism of aminoglycoside resistance due to abnormal hemin synthesis remains unclear. We investigate an Escherichia coli strain with a single amino acid substitution at position 85 of HemC.</p><p><strong>Methods: </strong>An aminoglycoside-resistant Escherichia coli DH5α was selected by passaging in Lysogeny Broth (LB) medium containing amikacin. Whole genome sequencing was performed to determine the genetic profile of the strain. An isogenic strain of E. coli DH5α was created. Growth rates, drug susceptibilities and expressions of the heme synthetic genes were compared between the original strain and the isogenic strain.</p><p><strong>Results: </strong>Whole genome sequencing revealed a nucleotide substitution at position 254 of hemC from adenine (A) to thymine (T), resulting in an amino acid substitution at position 85 of HemC from histidine (H) to leucine (L). There were no mutations in other heme synthetic genes, including hemA, hemB, hemC, hemD, hemE, hemF, hemG, hemH, hemL, hemN, hemX and hemY. The isogenic strain of E. coli DH5α with H85L in HemC was less susceptible to aminoglycosides, and its growth was slower than that of E. coli DH5α before passage. Quantitative real-time PCR showed that the expression of hemA was higher and the expressions of hemL, hemG and hemX lower in the isogenic strain than before passage.</p><p><strong>Conclusion: </strong>This is the first report of aminoglycoside resistance due to an amino acid substitution in HemC. These findings suggested that mutations in the heme synthetic genes may indirectly affect the growth rates of E. coli strains and their susceptibilities to aminoglycosides.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102536"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world study on disease burden and current clinical practice of hospital-acquired pneumonia in Japan. 关于日本医院获得性肺炎的疾病负担和当前临床实践的真实世界研究。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-11-06 DOI: 10.1016/j.jiac.2024.11.001
Masahiro Kimata, Yosuke Aoki, Takeshi Akiyama, Akiko Harada

Background: Hospital-acquired pneumonia (HAP) is a common nosocomial infection and is associated with high mortality. Despite advances in the understanding of the causes and prevention of HAP, it continues to be a frequent complication associated with hospital care. Presently, there are no large retrospective cohort studies on HAP in Japan.

Methods: A retrospective cohort study was conducted using the Medical Data Vision Co. Ltd. database for the study period (April 1, 2015 to May 31, 2018). The study population was defined based on ICD-10 codes for bacterial pneumonia, characteristics of hospitalization, and prescription of injection-only antibiotics. The study included patients ≥18 years of age with at least one episode of HAP during the identification period, where the episode was defined as hospitalization with HAP within the study identification period.

Results: A total of 2968 patients were included in this study contributing to 2979 HAP episodes. Patients with HAP were more likely to be male (64.9 %) and older than age 65 (86.5 %). The top three frequently prescribed antibiotics were sulbactam-ampicillin (39.7 %; 1183 episodes), tazobactam-piperacillin (28.4 %; 846 episodes) and ceftriaxone (23.2 %; 690 episodes). The mean (±SD) length of hospital stay during overall hospitalization and the HAP period were 49.9 (±34.2) days and 11.3 ± 7.3 days respectively. The HAP patient mortality at discharge was 22.0 %.

Conclusion: The present study provided insights regarding the characteristics, treatment patterns of HAP patients in Japan. Further, the study provided noteworthy information regarding antibiotic usage trends in the aging Japanese population.

背景:医院获得性肺炎(HAP)是一种常见的院内感染,死亡率很高。尽管人们对 HAP 的病因和预防有了更深入的了解,但它仍然是医院护理中的常见并发症。目前,日本还没有关于 HAP 的大型回顾性队列研究:方法:使用 Medical Data Vision Co.Ltd.数据库对研究期间(2015年4月1日至2018年5月31日)进行了回顾性队列研究。研究人群根据细菌性肺炎的 ICD-10 编码、住院特征和注射用抗生素处方进行定义。研究对象包括年龄≥18岁、在鉴定期内至少有一次HAP发作的患者,其中发作定义为在研究鉴定期内因HAP住院:本研究共纳入 2,968 名患者,共发生 2,979 次 HAP。HAP 患者多为男性(64.9%)和 65 岁以上的老年人(86.5%)。最常处方的三种抗生素是舒巴坦-氨苄西林(39.7%;1183 次)、他唑巴坦-哌拉西林(28.4%;846 次)和头孢曲松(23.2%;690 次)。整个住院期间和HAP期间的平均(± SD)住院时间分别为49.9天(± 34.2)和11.3天(± 7.3)。HAP 患者出院时的死亡率为 22.0%:本研究有助于深入了解日本 HAP 患者的特征和治疗模式。此外,该研究还提供了有关日本老龄化人口抗生素使用趋势的重要信息。
{"title":"Real-world study on disease burden and current clinical practice of hospital-acquired pneumonia in Japan.","authors":"Masahiro Kimata, Yosuke Aoki, Takeshi Akiyama, Akiko Harada","doi":"10.1016/j.jiac.2024.11.001","DOIUrl":"10.1016/j.jiac.2024.11.001","url":null,"abstract":"<p><strong>Background: </strong>Hospital-acquired pneumonia (HAP) is a common nosocomial infection and is associated with high mortality. Despite advances in the understanding of the causes and prevention of HAP, it continues to be a frequent complication associated with hospital care. Presently, there are no large retrospective cohort studies on HAP in Japan.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted using the Medical Data Vision Co. Ltd. database for the study period (April 1, 2015 to May 31, 2018). The study population was defined based on ICD-10 codes for bacterial pneumonia, characteristics of hospitalization, and prescription of injection-only antibiotics. The study included patients ≥18 years of age with at least one episode of HAP during the identification period, where the episode was defined as hospitalization with HAP within the study identification period.</p><p><strong>Results: </strong>A total of 2968 patients were included in this study contributing to 2979 HAP episodes. Patients with HAP were more likely to be male (64.9 %) and older than age 65 (86.5 %). The top three frequently prescribed antibiotics were sulbactam-ampicillin (39.7 %; 1183 episodes), tazobactam-piperacillin (28.4 %; 846 episodes) and ceftriaxone (23.2 %; 690 episodes). The mean (±SD) length of hospital stay during overall hospitalization and the HAP period were 49.9 (±34.2) days and 11.3 ± 7.3 days respectively. The HAP patient mortality at discharge was 22.0 %.</p><p><strong>Conclusion: </strong>The present study provided insights regarding the characteristics, treatment patterns of HAP patients in Japan. Further, the study provided noteworthy information regarding antibiotic usage trends in the aging Japanese population.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102551"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and microbiological characterization of invasive group a Streptococcus infection in children in Japan: A single-center experience. 日本儿童侵袭性 A 群链球菌感染的临床和微生物学特征:单中心经验。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-11-15 DOI: 10.1016/j.jiac.2024.11.010
Yuichiro Matsui, Shinsuke Mizuno, Masaki Anraku, Takahiro Yamaguchi, Mitsunobu Sugino, Ryuji Kawahara, Masashi Kasai

Background: Invasive group A Streptococcus (iGAS) infections are rare but potentially fatal. Although the number of invasive group A Streptococcus (iGAS) infections decreased during the coronavirus disease (COVID-19) pandemic, it sharply increased worldwide following the pandemic due to the emergence of M1UK strains. In Japan, non-fluminant iGAS infections have not been included in the national survey notification system. Therefore, the clinical and microbiological characteristics of iGAS infection are unknown. In this study, we aimed to clarify the clinical and microbiological characteristics of pediatric iGAS infections.

Methods: We conducted a case-series analysis of children aged 0-15 years with positive Streptococcus pyogenes cultures from otherwise sterile sites, diagnosed between July 2018 and June 2024. Clinical data were extracted from the electronic medical records. Samples of clinical isolates were sent to the Public Health Research Institute for further analysis.

Results: We identified 11 patients (median age, 5 years [interquartile range 1-8.5 years]; 6 girls). The incidence rate of the iGAS infections was highest in 2024, with 3 cases in 6 months. Primary bacteremia without focal infection was the predominant diagnosis, followed by skin and soft tissue infections with bacteremia. Among the 11 iGAS infections, 9 isolates were available for additional microbiological tests. M12 and M1 strains were predominant (four cases each). Three of the four M1 isolates were M1UK strains.

Conclusions: In the present study, the increasing incidence of iGAS infection and clinical diagnoses are similar to those reported in other countries; however, M12 strains as well as M1 strains are predominant.

背景:侵袭性 A 组链球菌(iGAS)感染虽然罕见,但却可能致命。虽然在冠状病毒病(COVID-19)大流行期间,侵袭性 A 组链球菌(iGAS)感染的数量有所下降,但在大流行之后,由于 M1UK 菌株的出现,全球侵袭性 A 组链球菌(iGAS)感染的数量急剧上升。在日本,非发光 iGAS 感染尚未纳入国家调查通报系统。因此,iGAS 感染的临床和微生物学特征尚不清楚。本研究旨在阐明小儿 iGAS 感染的临床和微生物学特征:我们对 2018 年 7 月至 2024 年 6 月期间确诊的 0-15 岁儿童进行了病例序列分析,这些儿童在其他无菌部位的化脓性链球菌培养呈阳性。临床数据提取自电子病历。临床分离物样本被送往公共卫生研究所做进一步分析:我们确定了 11 名患者(中位年龄 5 岁[四分位数间距 1-8.5 岁];6 名女孩)。2024 年的 iGAS 感染率最高,6 个月内就有 3 例。主要诊断为无病灶感染的原发性菌血症,其次是伴有菌血症的皮肤和软组织感染。在 11 例 iGAS 感染病例中,有 9 个分离菌株可进行其他微生物检测。主要是 M12 和 M1 菌株(各四例)。4 个 M1 分离物中有 3 个是 M1UK 菌株:在本研究中,iGAS 感染发病率的增加和临床诊断与其他国家报告的情况相似;但是,M12 菌株和 M1 菌株占主导地位。
{"title":"Clinical and microbiological characterization of invasive group a Streptococcus infection in children in Japan: A single-center experience.","authors":"Yuichiro Matsui, Shinsuke Mizuno, Masaki Anraku, Takahiro Yamaguchi, Mitsunobu Sugino, Ryuji Kawahara, Masashi Kasai","doi":"10.1016/j.jiac.2024.11.010","DOIUrl":"10.1016/j.jiac.2024.11.010","url":null,"abstract":"<p><strong>Background: </strong>Invasive group A Streptococcus (iGAS) infections are rare but potentially fatal. Although the number of invasive group A Streptococcus (iGAS) infections decreased during the coronavirus disease (COVID-19) pandemic, it sharply increased worldwide following the pandemic due to the emergence of M1<sub>UK</sub> strains. In Japan, non-fluminant iGAS infections have not been included in the national survey notification system. Therefore, the clinical and microbiological characteristics of iGAS infection are unknown. In this study, we aimed to clarify the clinical and microbiological characteristics of pediatric iGAS infections.</p><p><strong>Methods: </strong>We conducted a case-series analysis of children aged 0-15 years with positive Streptococcus pyogenes cultures from otherwise sterile sites, diagnosed between July 2018 and June 2024. Clinical data were extracted from the electronic medical records. Samples of clinical isolates were sent to the Public Health Research Institute for further analysis.</p><p><strong>Results: </strong>We identified 11 patients (median age, 5 years [interquartile range 1-8.5 years]; 6 girls). The incidence rate of the iGAS infections was highest in 2024, with 3 cases in 6 months. Primary bacteremia without focal infection was the predominant diagnosis, followed by skin and soft tissue infections with bacteremia. Among the 11 iGAS infections, 9 isolates were available for additional microbiological tests. M12 and M1 strains were predominant (four cases each). Three of the four M1 isolates were M1<sub>UK</sub> strains.</p><p><strong>Conclusions: </strong>In the present study, the increasing incidence of iGAS infection and clinical diagnoses are similar to those reported in other countries; however, M12 strains as well as M1 strains are predominant.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102560"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical characteristics and risk factors of infection in initially treated patients with multiple myeloma during the induction period. 初次接受治疗的多发性骨髓瘤患者在诱导期的临床特征和感染风险因素。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-11-19 DOI: 10.1016/j.jiac.2024.11.012
Qianying Pan, Beihui Huang, Junru Liu, Meilan Chen, Jingli Gu, Lifen Kuang, Xiaozhe Li, Juan Li

Background: Multiple myeloma (MM) is a common hematologic malignancy and immune dysfunction is a hallmark of the disease. It leads to an increased infection risk, which is still a major cause of mortality. The infection spectrum and characteristics have evolved with the introduction of novel agents. An understanding of risk factors that increasing susceptibility to infection is critical in fighting them. This retrospective study aimed to identify risk factors associated with infection and develop nomogram to qualify the risk of infection.

Methods: We retrospectively reviewed the data of patients who were diagnosed with MM between April 1, 2018 and December 31, 2021 in our department. Independent predictors for infection were determined by the univariate and multivariate logistic regression analysis. Nomogram was established and evaluated by receiver operating characteristic (ROC) curve, calibration curve and decision curve analysis (DCA).

Results: A total of 230 MM patients who were diagnosed or treated in our department were included. Infections were identified in 37.4 % of MM patients in the first treatment course. The most common infection was the pulmonary infection. The first treatment course had the highest infection rate. With three or more comorbidities, anemia, high LDH level and high β2-MG level were independent risk factors for infection in MM patients during the induction period. The area under the curve (AUC) of nomogram was 0.746 (95 % CI: 0.679-0.814). The calibration curve and DCA indicated the good performance of the nomogram.

Conclusion: Multiple myeloma patients with one or more of these mentioned risk factors should be monitored with particular care in order to decrease the incidence and severity of infective complications. Nomogram was established to predict the incidence of infection in MM patients. Nomogram has satisfactory accuracy, and clinical utility may benefit for clinical decision-making.

背景:多发性骨髓瘤(MM)是一种常见的血液系统恶性肿瘤,免疫功能障碍是该病的特征之一。它导致感染风险增加,而感染仍然是导致死亡的主要原因。随着新型制剂的引入,感染谱和特征也在不断演变。了解增加感染易感性的风险因素对于抗击感染至关重要。这项回顾性研究旨在确定与感染相关的风险因素,并绘制界定感染风险的提名图:我们回顾性审查了我科 2018 年 4 月 1 日至 2021 年 12 月 31 日期间确诊为 MM 的患者数据。通过单变量和多变量逻辑回归分析确定了感染的独立预测因素。通过接收者操作特征曲线(ROC)、校准曲线和决策曲线分析(DCA)建立并评估了提名图:共纳入了 230 名在我科接受诊断或治疗的 MM 患者。37.4%的MM患者在第一个疗程中发现感染。最常见的感染是肺部感染。第一个疗程的感染率最高。有三种或三种以上合并症、贫血、高 LDH 水平和高β2-MG 水平是 MM 患者在诱导期感染的独立危险因素。提名图的曲线下面积(AUC)为 0.746(95% CI:0.679-0.814)。校准曲线和 DCA 表明提名图性能良好:结论:多发性骨髓瘤患者如果有一个或多个上述危险因素,就应特别注意监测,以降低感染性并发症的发生率和严重程度。建立了预测多发性骨髓瘤患者感染发生率的提名图。提名图的准确性令人满意,其临床实用性可能有助于临床决策。
{"title":"Clinical characteristics and risk factors of infection in initially treated patients with multiple myeloma during the induction period.","authors":"Qianying Pan, Beihui Huang, Junru Liu, Meilan Chen, Jingli Gu, Lifen Kuang, Xiaozhe Li, Juan Li","doi":"10.1016/j.jiac.2024.11.012","DOIUrl":"10.1016/j.jiac.2024.11.012","url":null,"abstract":"<p><strong>Background: </strong>Multiple myeloma (MM) is a common hematologic malignancy and immune dysfunction is a hallmark of the disease. It leads to an increased infection risk, which is still a major cause of mortality. The infection spectrum and characteristics have evolved with the introduction of novel agents. An understanding of risk factors that increasing susceptibility to infection is critical in fighting them. This retrospective study aimed to identify risk factors associated with infection and develop nomogram to qualify the risk of infection.</p><p><strong>Methods: </strong>We retrospectively reviewed the data of patients who were diagnosed with MM between April 1, 2018 and December 31, 2021 in our department. Independent predictors for infection were determined by the univariate and multivariate logistic regression analysis. Nomogram was established and evaluated by receiver operating characteristic (ROC) curve, calibration curve and decision curve analysis (DCA).</p><p><strong>Results: </strong>A total of 230 MM patients who were diagnosed or treated in our department were included. Infections were identified in 37.4 % of MM patients in the first treatment course. The most common infection was the pulmonary infection. The first treatment course had the highest infection rate. With three or more comorbidities, anemia, high LDH level and high β2-MG level were independent risk factors for infection in MM patients during the induction period. The area under the curve (AUC) of nomogram was 0.746 (95 % CI: 0.679-0.814). The calibration curve and DCA indicated the good performance of the nomogram.</p><p><strong>Conclusion: </strong>Multiple myeloma patients with one or more of these mentioned risk factors should be monitored with particular care in order to decrease the incidence and severity of infective complications. Nomogram was established to predict the incidence of infection in MM patients. Nomogram has satisfactory accuracy, and clinical utility may benefit for clinical decision-making.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102562"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Infection and Chemotherapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1